• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Zivo Bioscience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    11/15/24 6:30:49 AM ET
    $ZIVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZIVO alert in real time by email
    zivo_8k.htm
    0001101026false00011010262024-11-122024-11-120001101026zivo:CommonStockParValueMember2024-11-122024-11-120001101026zivo:WarrantsToPurchaseSharesMember2024-11-122024-11-12iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): November 12, 2024

     

    ZIVO BIOSCIENCE, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

    Nevada

     

    000-30415

     

    87-0699977

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    21 East Long Lake Road, Suite 100,

    Bloomfield Hills, Michigan

     

    48304

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (248) 452-9866

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange on

    which registered

    Common Stock, par value $0.001 per share

     

    ZIVO

     

    OTCQB

    Warrants to purchase shares of Common Stock, par value $0.001 per share

     

    ZIVOW

     

    OTC Pink

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

    Item 1.01. Entry into a Material Definitive Agreement.

     

    The information provided in Item 2.03 of this Current Report on Form 8-K is incorporated by reference into this Item 1.01.

     

    Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

     

    On November 12, 2024, Zivo Bioscience, Inc. (the“Company”) entered into a Debt Settlement Agreement (“Debt Settlement Agreement”) with each of Howard Shapiro, Merger Masters Pension Fund, and Financial Trading Consultants Pension Fund (each a“Creditor”) to restructure certain debt of the Company. Each Creditor agreed to settle the Company’s existing debt in exchange for the Company issuing each Creditor an unsecured promissory note (each a“Note,”collectively, the“Notes”) pursuant to the terms agreed upon in each Debt Settlement Agreement. The Company issued a Note to each of Howard Shapiro, Merger Masters Pension Fund, and Financial Trading Consultants Pension Fund in the principal amount of $185,497.12, $40,331.51, and $51,425.75, respectively. The Notes have an aggregate principal amount of $277,254.38.

     

    Each Note is payable in 24 equal monthly installments beginning November 30, 2024 and bears interest at a rate of 1.0% per annum. Each Note is subject to customary events of default, the occurrence of which will trigger, at the option of the respective Creditor, the unpaid principal balance of the Note becoming immediately due and payable. The principal balance may be prepaid at any time without penalty.

     

    A copy of each Debt Settlement Agreement is attached as Exhibits 10.1, 10.2, 10.3, and each Note is attached as Exhibits 10.4, 10.5, and 10.6, to this Current Report on Form 8-K and is incorporated herein by reference. The disclosure set forth in this Item 2.03 is intended to be a summary only and is qualified in its entirety by reference to each Debt Settlement Agreement and Note.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.

    Description

    10.1

    Debt Settlement Agreement, dated November 12, 2024, by and between Howard Shapiro and the Company

    10.2

     

    Debt Settlement Agreement, dated November 12, 2024, by and between Merger Masters Pension Fund and the Company

    10.3

     

    Debt Settlement Agreement, dated November 12, 2024, by and between Financial Trading Consultants Pension Fund and the Company

    10.4

    Promissory Note, dated November 12, 2024, in favor of Howard Shapiro

    10.5

    Promissory Note, dated November 12, 2024, in favor of Merger Masters Pension Fund

    10.6

     

    Promissory Note, dated November 12, 2024, in favor of Financial Trading Consultants Pension Fund

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     
    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    ZIVO BIOSCIENCE, INC.

     

     

     

    By:

    /s/ Keith Marchiando

     

     

    Keith Marchiando

     

     

    Chief Financial Officer

     

     

    Date: November 15, 2024

     

     
    3

     

    Get the next $ZIVO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZIVO

    DatePrice TargetRatingAnalyst
    12/15/2021$9.00Buy
    Maxim Group
    More analyst ratings

    $ZIVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Zivo Bioscience Inc.

      SC 13D/A - Zivo Bioscience, Inc. (0001101026) (Subject)

      10/1/24 2:57:20 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Zivo Bioscience Inc.

      SC 13D - Zivo Bioscience, Inc. (0001101026) (Subject)

      6/12/24 8:49:08 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Zivo Bioscience Inc.

      SC 13D - Zivo Bioscience, Inc. (0001101026) (Subject)

      6/12/24 8:44:12 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZIVO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

      ZIVO Bioscience, Inc. (OTCQB:ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced positive results from its second collaborative study with the University of Delaware evaluating the efficacy of several formulations of ZIVO's proprietary active ingredients in mitigating the spread of Low Pathogenicity Avian Influenza (LPAI) virus among poultry. Building upon the outcomes of the initial study, this second study aimed to assess and compare the performance of three different ZIVO formulations in both directly challenged and contact-exposed birds. The study affirm

      5/6/25 5:54:00 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry

      ZIVO Bioscience, Inc. (OTCQB:ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces plans for a second collaborative study with the University of Delaware. This new study aims to further explore the potential applications of ZIVO's proprietary active ingredients in mitigating the spread of Low Pathogenicity Avian Influenza (LPAI) virus among poultry. ZIVO's previous study with the University of Delaware demonstrated a significant reduction in viral shedding and a delay in disease transmission among treated birds. This new study is designed to further optimize formul

      2/6/25 4:36:00 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ZIVO Bioscience to Present at The Microcap Conference 2025

      Zivo Bioscience, Inc. (OTCQB:ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J. Management will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the company's recent developments, growth strategy, and investment opportunities. Event: The Microcap Conference 2025 Location: Studio 1, Borgata Hotel Casino & Spa Date: Thursday January 30, 2025 Time: 2:30 PM Eastern Time Investors i

      1/22/25 4:15:00 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZIVO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Yaldoo Laith L bought $176,682 worth of shares (10,080 units at $17.53) (SEC Form 4)

      4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

      4/4/25 8:23:32 AM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Strome Mark E bought $1,514,250 worth of shares (75,000 units at $20.19) (SEC Form 4)

      4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

      12/31/24 6:47:29 AM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Yaldoo Laith L bought $49,993 worth of shares (3,133 units at $15.96) (SEC Form 4)

      4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

      10/17/24 7:33:33 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZIVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Maggiore Christopher D. sold $325 worth of shares (20 units at $16.25), decreasing direct ownership by 0.00% to 507,000 units (SEC Form 4)

      4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

      4/9/25 9:42:34 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Yaldoo Laith L bought $176,682 worth of shares (10,080 units at $17.53) (SEC Form 4)

      4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

      4/4/25 8:23:32 AM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 5 filed by Strome Mark E

      5 - Zivo Bioscience, Inc. (0001101026) (Issuer)

      1/23/25 7:48:25 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZIVO
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Zivo Bioscience Inc.

      DEF 14A - Zivo Bioscience, Inc. (0001101026) (Filer)

      4/25/25 4:36:25 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Zivo Bioscience Inc.

      DEFA14A - Zivo Bioscience, Inc. (0001101026) (Filer)

      4/25/25 8:30:43 AM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Zivo Bioscience Inc.

      10-K - Zivo Bioscience, Inc. (0001101026) (Filer)

      3/18/25 4:10:47 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZIVO
    Financials

    Live finance-specific insights

    See more
    • ZIVO Bioscience Announces Plans for a New Streamlined, Focused Corporate Structure and Establishes the ZIVOLife Agtech Business

      ZIVOLife to be Granted Exclusive Worldwide Limited License to ZIVO Bioscience Intellectual Property for the Production and Supply of Whole Biomass Algal Products Conference call to be held in early November Zivo Bioscience, Inc. (NASDAQ:ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced plans to create ZIVOLife LLC ("ZIVOLife"), a newly formed wholly-owned subsidiary, to streamline the Company's corporate structure, better capitalize on the global agtech market opportunity and accelerate progress toward generating revenue from the Company's prop

      10/24/22 4:15:00 PM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZIVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Zivo Bioscience with a new price target

      Maxim Group initiated coverage of Zivo Bioscience with a rating of Buy and set a new price target of $9.00

      12/15/21 10:56:47 AM ET
      $ZIVO
      Biotechnology: Pharmaceutical Preparations
      Health Care